Neurotrophic factors as a therapeutic target for Parkinson's disease (Q28273071)

Expert Opinion on Therapeutic Targets

Europe PubMed Central

title

Neurotrophic factors as a therapeutic target for Parkinson's disease (English)

0 references

1 reference

2

Roger A Barker

0 references

author name string

Jonathan R Evans

series ordinal

1

0 references

language of work or name

English

0 references

publication date

April 2008

0 references

published in

0 references

volume

12

0 references

issue

4

0 references

page(s)

437-47

0 references

cites work

Therapeutic potential of neurotrophic factors for neurological disorders

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Role of brain-derived neurotrophic factor in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Treatment options in the modern management of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Persephin, a novel neurotrophic factor related to GDNF and neurturin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Multiple actions of systemic artemin in experimental neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF signalling through the Ret receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Expression and regulation of GFRalpha3, a glial cell line-derived neurotrophic factor family receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

The expanding role of BDNF: a therapeutic target for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Neural repair strategies for Parkinson's disease: insights from primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

The behavioural and motor consequences of focal lesions of the basal ganglia in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF in Parkinson disease: an object lesson in the tyranny of type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF in Parkinson's disease: the perils of post-hoc power

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Continuing trials of GDNF in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Crossroads in GDNF therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Impact of placebo assignment in clinical trials of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Placebo mechanisms and reward circuitry: clues from Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF in treatment of Parkinson's disease: response to editorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

Changing responsiveness of developing midbrain dopaminergic neurons for extracellular growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437

GDNF in treatment of Parkinson's disease: response to editorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.4.437